Acadia Pharmaceuticals (ACAD) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD’s commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).Acadia’s first drug, Nuplazid, is the first and the only FDA-approved treatment for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. Its second ...

ktsimage Shares of central nervous system therapy concern Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) have recently fallen to their lowest level since its second commercial asset, Daybue, was approved. The main impetus for the decline was the failure of its other commercial product (Nuplazid) in a Phase 3 label-expansion trial for negative symptoms of schizophrenia. With a potential gene therapy threat to Daybue in early-stage studies but trading at two times FY24E revenue net of cash, Acadia merited another ...

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 0.6% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Acadia Q1 Earnings Surpass Estimates, ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:Citizens JMP Life Sciences ConferenceFireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY2024 RBC Capital Markets Global Healthcare ConferenceFireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NYBofA Securities Health Care ConferenceFireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las V ...

Acadia Pharmaceuticals Inc. (ACAD) reported first-quarter 2024 earnings of 10 cents per share, beating the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $205.8 million, which missed the Zacks Consensus Estimate of $206.9 million. Acadia’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplaz ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Co ...

First Quarter 2024 Earnings Call May 8, 2024 Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Steve Davis | President and Chief Executive Officer Comme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No.) 1 ...

Company Performance - Acadia Pharmaceuticals reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, compared to a loss of $0.27 per share a year ago, representing an earnings surprise of 150% [1] - The company posted revenues of $205.83 million for the quarter ended March 2024, which missed the Zacks Consensus Estimate by 0.52%, but increased from $118.46 million year-over-year [1] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [1] Stock Performance - Acadia shares have declined approximately 44.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.8% [2] - The current Zacks Rank for Acadia is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $241.7 million, and for the current fiscal year, it is $0.62 on revenues of $967.9 million [4] - The trend of estimate revisions for Acadia is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [5] - Another company in the same industry, Biofrontera Inc., is expected to report a quarterly loss of $1.63 per share, reflecting a year-over-year change of +63%, with revenues projected at $11.52 million, up 32% from the previous year [5][6]